PROTEINTECH GROUP, INC.

ProteinTech Group, Inc. specializes in the manufacturing and research of biological materials and blood products, with core capabilities centered on the production of non-diagnostic biological substances and applied biotechnology research. The company demonstrates technical expertise in the handling, processing, and formulation of sensitive biological agents under controlled conditions, aligning with federal standards for biosafety and product integrity. Their work supports critical supply chains for therapeutic and research applications, emphasizing precision in material characterization, aseptic processing, and chain-of-custody protocols for biological specimens. Differentiators include deep familiarity with the regulatory and logistical demands of federal biological material procurement, ensuring compliance with cGMP principles and chain-of-cold requirements essential for blood-derived and cell-based products. The contractor maintains a consistent relationship with the Department of Health and Human Services, providing specialized biological materials and supporting R&D initiatives focused on biotechnology applications. Their engagements with HHS reflect a sustained role in supplying mission-critical biological assets, likely supporting public health programs, research laboratories, or emergency preparedness efforts requiring validated, non-diagnostic biological reagents. ProteinTech Group operates primarily within NAICS 325414 (Biological Product Manufacturing) and 541711 (Biotechnology Research and Development), positioning itself at the intersection of production and innovation in the life sciences sector. The company’s market focus is narrow but highly specialized, serving government-funded programs that require controlled, high-integrity biological inputs for therapeutic development or scientific research. As a small business structured as a 2L entity based in Rosemont, Illinois, ProteinTech Group operates without federal certifications but maintains a focused geographic footprint aligned with federal biologics supply needs. Their business model reflects a niche, capability-driven approach to serving federal agencies requiring specialized biological manufacturing and research support.